Influence Of Tongxinluo On Inflammation Makers In Patients With Acute Coronary Syndrome

Background:Acute coronary syndrome (ACS) is the result of atherosclerosis plaque rupture or erosion which lead to a local thrombus formation with consecutive necrosis of myocytes caused ischemia, leading to adverse cardiovascular events.In recent years, there are increasing number of evidence show that inflammatory response has been recognized as the pathophysiological basis of formation atherosclerotic plaque.Furthermore, it enhanced plaque rupture and promoted thrombosis. Thus, inflammation and atherosclerosis is related closed. The prognosis of the ACS could be evaluated by inflammation makers. High sensitivity C reactive protein (hs-CRP), as an inflammatory maker, it plays an important role which causes plaque instability in acute inflammation response. The concentration of high sensitivity C-reactive protein (hs-CRP) may reflect the severity of vulnerable plaque. Peripheral white blood cells (PWBC) is inflammation makers as well, which involved in the formation of atherosclerosis. Testing inflammatory makers of peripheral blood to identify the existence of the vulnerable plaques, so as to achieve the purpose of intervention early. Inflammatory response in ACS is vital. Consequently, it is great significance to inhibit the inflammatory response positively in ACS. At present, the drug statins and other for anti-inflammatory response still have higher risk of cardiovascular events residual, so the exploment of new drugs with anti-inflammatory is significance for the prevention and treatment of ACS. Tongxinluo in capsule form is a compound formulated according to the meridian theory of traditional Chinese medicine. Tong-xinluo and statins offer similar protection in terms of lipid-lowering anti-inflammation and antioxida-tion effects, attracting widespread interest.Objective:To observe the influence of tongxinluo capsule on inflammation makers in patients with acute coronary syndrome. Method:Sixty patients who had been confirmed diagnosed with ACS were randomly divided into control group (n=30) and treatment group (n=30):control group were treated with routine therapy, treatment group were treated with Tongxinluo capsule based on routine therapy. Both treatments lasted for ten days. Blood lipids, plasma hs-CRP and PWBC were measured on the first day before treatment and the tenth day after the treatment within the two groups.Results:Compared with the level before medical intervention,after ten days treatments, the concentrations of LDL-C、T C、TG were decreased (p<0.05) for two groups. Compared with the control group, the concentrations of TC、TG、LDL-C were not significantly decreased (p>0.05), while significant changes were not found in the serum indexes of HDL-C. The concentrations of hs-CRP and PWBC were reduced between control group and treatment group.All these changes had a great significant difference (p<0.05). No serious side effects occurred within the patients during the treatment.Conclusion:Tongxinluo capsule has the effect of reducing plasma hs-CRP and PWBC levels and is effective in inhibiting inflammatory reactive and stabling plaque in patients with ACS to some extent.